Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical characteristics and therapeutic determinants of RUNX1::RUNX1T1 differ from those of CBFB::MYH11 acute myeloid leukemia

30 Apr 2025

Abstract excerpt

Core binding factor acute myeloid leukemia (CBF-AML) includes RUNX1::RUNX1T1 and CBFB::MYH11 AML. To investigate whether they should be regarded as distinct entities and treated separately, we retrospectively analyzed 536 patients with CBFAML aged 60 years or younger. For CBFB::MYH11 AML, no outcome differences were observed between standard-dose (SD) and intermediate-dose (ID) cytarabine induction, with 5-year...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40304077
DOI: 10.3324/haematol.2024.287293

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical characteristics and therapeutic determinants of RUNX1::RUNX1T1 differ from those of CBFB::MYH11 acute myeloid leukemiaPMID 40304077Read ↗

Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation.Semantic proximity Read ↗

Core Binding Factor AML Beyond Favorable Risk: Molecular Heterogeneity, MRD Dynamics, and Implications for Clinical Decision-MakingSemantic proximity Read ↗

Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual diseaseSemantic proximity Read ↗

Genetic abnormalities predict outcomes in patients with core binding factor acute myeloid leukemiaSemantic proximity Read ↗

The characteristics and prognostic analysis of therapy-related acute myeloid leukemia patients in China.Semantic proximity Read ↗

Mutational spectrum and prognostic stratification of intermediate-risk acute myeloid leukemia.Semantic proximity Read ↗

Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt-related transcription factor 1 mutation: A single-center retrospective analysis.Semantic proximity Read ↗

Investigations of the prognostic value of RUNX1 mutation in acute myeloid leukemia patients: Data from a real-world study.Semantic proximity Read ↗

Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years.Semantic proximity Read ↗

Impact of RUNX1 mutations at distinct sites on the clinical characteristics and prognosis of patients with acute myeloid leukemia.Semantic proximity Read ↗

Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications.Semantic proximity Read ↗

[Clinical characteristics of RUNX1-mutated acute myeloid leukemia patients].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.